KRYS Key Statistics, Chart & Performance
The current stock price of KRYS is 279.24 USD. In the past month the price increased by 13.26%. In the past year, price increased by 74.81%.
KRYS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KRYS. When comparing the yearly performance of all stocks, KRYS is one of the better performing stocks in the market, outperforming 94.13% of all stocks.
KRYS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to KRYS. While KRYS has a great health rating, its profitability is only average at the moment.
KRYS Financial Highlights
Over the last trailing twelve months KRYS reported a non-GAAP Earnings per Share(EPS) of 6.67. The EPS increased by 276.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 53.3% | ||
| ROA | 16.04% | ||
| ROE | 17.48% | ||
| Debt/Equity | 0 |
KRYS Forecast & Estimates
18 analysts have analysed KRYS and the average price target is 269.93 USD. This implies a price decrease of -3.33% is expected in the next year compared to the current price of 279.24.
For the next year, analysts expect an EPS growth of 114.44% and a revenue growth 34.01% for KRYS
KRYS Ownership
About KRYS
Company Profile
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 275 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Company Info
KRYSTAL BIOTECH INC
2100 Wharton St Ste 701
Pittsburgh PENNSYLVANIA 15203 US
CEO: Krish S. Krishnan
Employees: 275
Phone: 14125865830
KRYSTAL BIOTECH INC / KRYS FAQ
Can you describe the business of KRYSTAL BIOTECH INC?
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 275 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
What is the current price of KRYS stock?
The current stock price of KRYS is 279.24 USD. The price decreased by -0.04% in the last trading session.
Does KRYS stock pay dividends?
KRYS does not pay a dividend.
What is the ChartMill rating of KRYSTAL BIOTECH INC stock?
KRYS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the GICS sector and industry of KRYS stock?
KRYSTAL BIOTECH INC (KRYS) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for KRYS stock?
The Revenue of KRYSTAL BIOTECH INC (KRYS) is expected to grow by 34.01% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for KRYSTAL BIOTECH INC?
KRYSTAL BIOTECH INC (KRYS) currently has 275 employees.